Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug’s safety and efficacy. This rigorous process is a cornerstone…
Wearable Devices (NASDAQ: WLDS, WLDSW), a technology company specializing in AI-powered touchless sensing wearables, announced the issuance of a continuation patent by the U.S. Patent and Trademark Office, expanding its foundational patent titled “Gesture and…
Safe Pro Group (NASDAQ: SPAI), an emerging provider of AI-powered security and threat detection solutions, will demonstrate its drone-based artificial intelligence tools during the U.S. Army’s 2026 Concept Focused Warfighting Experiment Maneuver (“CFWE-M”), scheduled for…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed a Citizen Petition with the FDA requesting the removal of Benzethonium Chloride (BZT) from all ketamine products sold in the U.S. BZT, a quaternary amine…
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug development company, has launched predictBBB.ai(TM), a public AI module that predicts blood-brain barrier (BBB) permeability of small molecules with 94% accuracy, 95% sensitivity, and 89% specificity. Built…
Disseminated on behalf of PowerBank Corporation SolarBank Corporation, a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is now PowerBank (NASDAQ: SUUN)…
Wearable Devices (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless,…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet’s Disease, meeting the objective of demonstrating biological efficacy. In…
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, announced a strategic initiative focused on advanced cryogenic packaging to accelerate development of both its gate-model and annealing quantum processors.…
Datavault AI (NASDAQ: DVLT), a platinum partner in IBM Partner Plus, announced the expanded commercialization of its flagship AI agents, DataScore and DataValue, now embedded with IBM watsonx.ai. Designed to turn enterprise data into financial…
BluSky AI (OTC: BSAI), a leading innovator in modular AI infrastructure, signed a Letter of Intent (LOI) to purchase approximately 15 acres of industrial land in Camp Verde, Arizona. The site includes existing electrical infrastructure…
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, will hold a conference call Aug. 13, 2025, at 4:30 p.m. Eastern to discuss second-quarter results for the period ended…
Newton Golf Company (NASDAQ: NWTG) has hit a major milestone in its mission to redefine golf shaft performance — more than 50 professionals across the PGA TOUR Champions and LPGA Tour have now used Newton…
BluSky AI (OTC: BSAI), a modular AI infrastructure innovator, announced it has signed a non-binding letter of intent with Creekstone Energy LLC to acquire 25 acres within the Delta Data Center Development, including access to…
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded…
Bollinger Innovations (NASDAQ: BINI), an electric vehicle manufacturer, announced that its previously disclosed name change from Mullen Automotive Inc. to Bollinger Innovations, Inc. is effective as of July 28, 2025, along with its new Nasdaq…
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to accelerate oncology drug discovery, announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop, co-founder…
Investors looking for exposure to important biopharma innovation in underserved markets need to consider Clene (NASDAQ: CLNN). Clene and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company is focused on improving…